STRYKER CORPORATION Reports Fourth Quarter Earnings Results for FY2022 Ending January 31 2023.

Earnings Overview

STRYKER CORPORATION ($NYSE:SYK) reported total revenue of USD 563.0 million for the fourth quarter of FY2022, ending January 31 2023, a decrease of 15.0% compared to the same period the previous year. Net income for the quarter was USD 5202.0 million, representing a growth of 10.7% year-on-year.

Transcripts Simplified

The fourth quarter saw organic sales growth of 13.2%, with U.S. organic sales growth of 11.2%, and international organic sales growth of 18.3%. Adjusted EPS for the quarter was up 10.7%. MedSurg and Neurotechnology had constant currency sales growth of 19.3%, and organic sales growth of 16.9%, with U.S. organic growth of 14.9%, and international organic growth of 22.5%.

Instruments had U.S. organic sales growth of 11.7%, Endoscopy had U.S. organic sales growth of 9.7%, and Medical had U.S. organic sales growth of 22.9%. Neurovascular had U.S. organic sales growth of 1.5%, while Neurocranial had impressive organic growth of 19.7%.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Stryker Corporation. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Stryker Corporation. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Stryker Corporation. More…

Key Ratios Snapshot

Some of the financial key ratios for Stryker Corporation are shown below. More…

Price History

The company’s stock opened at $249.1 and closed at $253.8, representing an increase of 1.7% from its prior closing price of $249.5. This marks the second consecutive quarter that the company reported an increase in share prices, highlighting the strong performance of its operations. The good news from STRYKER CORPORATION does not end there.

This was mainly due to the company’s industrial and medical equipment divisions, both of which reported higher sales and profits. With its strong operational performance and financial position, investors can expect that the company will continue to deliver consistent returns over the long term. Live Quote…

Analysis

GoodWhale has conducted an analysis of STRYKER CORPORATION‘s fundamentals, and has determined that it is a medium risk investment. This assessment is based on our Risk Rating, which takes into account both the financial and business aspects of STRYKER CORPORATION. Furthermore, we have detected 1 risk warning in the balance sheet of STRYKER CORPORATION. If you would like to investigate this warning further, please register on goodwhale.com. More…

Peers

Stryker Corporation is one of the world’s largest medical technology companies. It offers a broad range of products including orthopedic implants, surgical instruments, medical equipment and software solutions. The company operates in over 100 countries and has a strong presence in the United States, Europe and Asia. Stryker’s competitors include Fukuda Denshi Co Ltd, Nihon Kohden Corp and Shanghai Sanyou Medical Co Ltd.

– Fukuda Denshi Co Ltd ($TSE:6960)

Fukuda Denshi Co. Ltd., together with its subsidiaries, manufactures and sells medical electronic equipment in Japan and internationally. The company operates through five segments: Diagnostic Cardiology, Diagnostic Imaging, Patient Monitoring, Electrotherapy, and Others. It offers diagnostic cardiology products, including electrocardiographs, stress test systems, Holter systems, ambulatory blood pressure monitors, and medical printers; and diagnostic imaging products comprising X-ray diagnostic systems, computed tomography systems, magnetic resonance imaging systems, ultrasound diagnostic systems, X-ray angiography systems, and nuclear medicine diagnostic systems. The company also provides patient monitoring products, such as central station systems, telemetry systems, patient monitors, and related accessories; electrotherapy products, such as shortwave diathermy machines and physical therapy equipment; and other products, such as endoscopic and ophthalmologic equipment. It sells its products primarily to general hospitals, clinics, and other health care facilities. The company was founded in 1930 and is headquartered in Tokyo, Japan.

– Nihon Kohden Corp ($TSE:6849)

Nihon Kohden Corp. is a Japanese manufacturer of medical equipment, headquartered in Tokyo. The company was founded in 1952 and has since grown to become a leading supplier of medical equipment in Japan. Nihon Kohden’s product lineup includes everything from patient monitors and electrocardiographs to ultrasound machines and medical robotics. The company also offers a wide range of services, including maintenance and repair services for its products.

Nihon Kohden has a market capitalization of 269.63 billion as of 2022. The company’s return on equity is 11.49%. Nihon Kohden is a leading manufacturer of medical equipment in Japan. The company offers a wide range of products and services, including maintenance and repair services for its products.

– Shanghai Sanyou Medical Co Ltd ($SHSE:688085)

Shanghai Sanyou Medical Co Ltd is a medical company with a market cap of 6.32B as of 2022. The company’s return on equity is 8.85%. Shanghai Sanyou Medical Co Ltd is engaged in the research, development, manufacture, and sale of medical devices and equipment. The company’s products include medical imaging equipment, medical consumables, and medical disposables.

Summary

Investing in Stryker Corporation has been a positive experience for shareholders in the last fiscal year. The company reported total revenue of $563 million for the fourth quarter of FY2022, a 15% decrease compared to the same period last year. Despite this decrease, net income was $5202 million, representing a 10.7% growth year-on-year. Overall, Stryker Corporation has shown steady progress in terms of revenue and profit, making it an attractive investment option for those looking to diversify their portfolio.